Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
NCT04764448 is registered in ClinicalTrials.gov with Dicerna Pharmaceuticals, Inc., a Novo Nordisk company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Placebo-Controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 12, 2021
- Completion date
- May 29, 2024
- Enrollment
- 16 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.